DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right up until illness progression or maybe the participants are not able to tolerate the study drugs.and after that endorse H3K27Ac at this region. Chromatin hyperacetylation could impr